Loading...
Loading...
MBRX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 32.0K |
| Gross Profit | -32.0K |
| Operating Expense | 6,645.0K |
| Operating I/L | -6,677.0K |
| Other Income/Expense | 1,707.0K |
| Interest Income | 241.0K |
| Pretax | -4,970.0K |
| Income Tax Expense | -11.3K |
| Net Income/Loss | -4,970.0K |
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company specializing in developing drug candidates for highly resistant tumors and viruses. Its lead drug candidate, Annamycin, is in Phase 1/2 studies for relapsed or refractory acute myeloid leukemia and lung metastasized cancers. The company's flagship immune/transcription modulator, WP1066, is in Phase I clinical trial for brain tumors, pediatric brain tumors, pancreatic cancer, and other malignancies. Additionally, it develops WP1220 for the topical treatment of cutaneous T-cell lymphoma and WP1122 to treat glioblastoma multiforme and COVID-19.
